Uncategorized
Gevokizumab fails to meet primary endpoint in phase 3 trial for Behçet’s disease uveitis
Xoma today announced gevokizumab failed to meet its primary endpoints in a phase 3 trial in patients with uveitis caused by Behçet’s disease, according to a company press release.The EYEGUARD-B study — a randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s disease uveitis — enrolled 83 patients with Behçet’s disease uveitis, with 40 patients randomly assigned to receive gevokizumab and 43 patients assigned to receive placebo. The primary endpoint was time to the first acute ocular exacerbation.